RHHVF - Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study Offering Hope | Benzinga
Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, met the primary endpoint.
Zilebesiran is being co-developed and co-commercialized by Alnylam and Roche Holdings AG (OTC: RHHBY).
The study demonstrated a dose-dependent, clinically significant reduction in 24-hour mean systolic blood pressure (SBP) measured by ambulatory blood pressure monitoring (ABPM) at Month 3, achieving a placebo-subtracted reduction greater ...